Reverse Engineering the 1-Month Lupron Depot®
- 300 Downloads
The 1-month Lupron Depot® (LD) encapsulating water-soluble leuprolide in poly(lactic-co-glycolic acid) (PLGA) microspheres is a benchmark product upon which modern long-acting release products are often compared. Despite expiration of patent coverage, no generic product for the LD has been approved in the USA, likely due to the complexity of components and manufacturing processes involved in the product. Here, we describe the reverse engineering of the LD composition and important product attributes. Specific attributes analyzed for microspheres were as follows: leuprolide content by three methods; gelatin content, type, and molecular weight distribution; PLGA content, lactic acid/glycolic acid ratio, and molecular weight distribution; mannitol content; in vitro drug release; residual solvent and moisture content; particle size distribution and morphology; and glass transition temperature. For the diluent, composition, viscosity, and specific gravity were analyzed. Analyzed contents of the formulation and the determined PLGA characteristics matched well with the official numbers stated in the package insert and those found in literature, respectively. The gelatin was identified as type B consistent with ~ 300 bloom. The 11-μm volume-median microspheres in the LD slowly released the drug in vitro in a zero-order manner after ~ 23% initial burst release. Very low content of residual moisture (< 0.5%) and methylene chloride (< 1 ppm) in the product indicates in-water drying is capable of removing solvents to extremely low levels during manufacturing. The rigorous approach of reverse engineering described here may be useful for development of generic leuprolide-PLGA microspheres as well as other new and generic PLGA microsphere formulations.
KEY WORDSgeneric drugs leuprolide Lupron Depot® PLGA microspheres reverse engineering
We gratefully thank Jason Romberg from Anton Paar USA Inc. who helped with the determination of viscosity of the injection diluent.
This research was funded by FDA contract HHSF223201510170C A0001 BAA. This paper reflects the views of the authors and should not be construed to represent FDA’s views or policies.
- 3.Annual reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. United States Securities and Exchange Commission.Google Scholar
- 4.21 CFR 314.94(a)(9)(iii).Google Scholar
- 5.Wang Y, Wen Q, Choi SH. FDA’s regulatory science program for generic PLA/PLGA-based drug products. Am Pharm Rev. 2016;19(4):5–9.Google Scholar
- 6.Lupron Depot® package insert. [Internet]. AbbVie Inc.; Available from: http://www.rxabbvie.com/pdf/lupronuro_pi.pdf
- 8.Okada H, Inoue Y, Ogawa Y. Prolonged release microcapsules. US Patent No. 1997;5:643,607.Google Scholar
- 9.Gelatin handbook [Internet]. Vol. 2015. Gelatin Manufacturers Institute of America; 2012. Available from: http://www.gelatin-gmia.com/images/GMIA_Gelatin_Manual_2012.pdf
- 15.Rolling-ball viscometer Lovis 2000 M/ME product website [internet]. Anton Paar; Available from: http://www.anton-paar.com/us-en/products/details/rolling-ball-viscometer-lovis-2000-mme/.
- 16.Zheng S, Smith P, Burton L, Adams ML. Sensitive fluorescence-based method for the rapid determination of polysorbate-80 content in therapeutic monoclonal antibody products. Pharm Dev Technol 2014;1–5.Google Scholar
- 22.Dawson RMC, Elliott DC, Elliott WH, Jones KM. Data for biochemical research. New York: Oxford University Press; 1989. p. 592.Google Scholar
- 23.Harris ELV, Angal S. Protein purification methods: a practical approach (the practical approach series). New York: Oxford University Press; 1990. p. 179.Google Scholar